Ferric carboxymaltose: choice of treatment in postpartum anaemia in multispeciality zonal hospital of armed forces medical services

Dhananjay S. Borse; Binay Mitra; Debkalyan Maji

doi:10.18203/2320-1770.ijrcog20195326

Authors

Dhananjay S. Borse Department of Obstetrics and Gynecology, 166 Military Hospital Jammu, Jammu and Kashmir, India
Binay Mitra Department of Obstetrics and Gynecology, 166 Military Hospital Jammu, Jammu and Kashmir, India
Debkalyan Maji Department of Obstetrics and Gynecology, 166 Military Hospital Jammu, Jammu and Kashmir, India

DOI:

https://doi.org/10.18203/2320-1770.ijrcog20195326

Keywords:

Ferric carboxymaltose, Postpartum iron deficiency anemia

Abstract

Background: World Health Organization has defined postpartum anemia (PPA) as hemoglobin (Hb) of < 10 gm% during the postpartum period. The objective of the present study was to compare the safety and efficacy of ferric carboxymaltose (FCM) in the treatment of post-partum anaemia (PPA).

Methods: A total of 214 patients were identified in a zonal hospital of Armed Forces Medical Services, between Jan 2019 and August 2019 who found to have PPA. Patients having hemoglobin (Hb) <10 g/dl were assigned to receive Intravenous FCM, as per the calculated dose. Changes in hemoglobin (Hb) and serum ferritin levels at 2 and 6 weeks after treatment were recorded and analyzed. Adverse effects to FCM administration were also recorded.

Results: Significant rises in Hb and serum ferritin levels were observed. The mean increase in Hb after 2 weeks was 3.1±0.50 g/dl and 4.0±70 g/dl at 6 weeks. The mean increase in serum ferritin levels after 2 weeks was 210.40±38.50 and 270.25±14.60 ng/ml after 6 weeks. Adverse drug reactions were significantly less (p<0.001).

Conclusions: Ferric carboxymaltose increases Hb level and restores iron stores faster without any severe adverse drug reactions. Patient tolerance was good after FCM injection.

Metrics

Metrics Loading ...

References

Pavord S, Myers B, Robinson S, Allard S, Strong J, Oppenheimer C, et al. UK guidelines on the management of iron deficiency in pregnancy. Br J Haematol. 2012;156:588-600.

Kouser S, Kouser S, Malik M, Malik A. Safety and efficacy of intravenous iron therapy in postnatal patients with iron deficiency anemia. J South Asian Fed Obstet Gynaecol. 2011;3:25-7.

Somdatta P, Reddaiah VP, Singh B. Prevalence of anaemia in the postpartum period: A study of a North Indian village. Trop Doct. 2009;39:211-5.

Reinold C, Dalenius K, Smith B, Brindley P, Grummer-Strawn L. Atlanta: U.S. Department of Health and Human Services, Centers for Disease Control and Prevention; Pregnancy Nutrition Surveillance 2007 Report; 2009.

Sutherland T, Bishai DM. Cost-effectiveness of misoprostol and prenatal iron supplementation as maternal mortality interventions in home births in rural India. Int J Gynaecol Obstet. 2009;104:189-93.

Seid MH, Derman RJ, Baker JB, Banach W, Goldberg C, Rogers R. Ferric carboxymaltose injection in the treatment of postpartum iron deficiency anemia: A randomized controlled clinical trial. Am J Obstet Gynecol. 2008;199:435.e1-7.

Breymann C, Gliga F, Bejenariu C, Strizhova N. Comparative efficacy and safety of intravenous ferric carboxymaltose in the treatment of postpartum iron deficiency anemia. Int J Gynaecol Obstet. 2008;101:67-73.

Van Wyck DB, Martens MG, Seid MH, Baker JB, Mangione A. Intravenous ferric carboxymaltose compared with oral iron in the treatment of postpartum anemia: A randomized controlled trial. Obstet Gynecol. 2007;110:267-78.